Anti-(human Protein CS1) (human-mouse HuLuc63 Heavy Chain)
Anti-(human Protein CS1) (human-mouse HuLuc63 Heavy Chain) Uses, Dosage, Side Effects, Food Interaction and all others data.
Anti-(human Protein CS1) (human-mouse HuLuc63 Heavy Chain) is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Anti-(human Protein CS1) (human-mouse HuLuc63 Heavy Chain) targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Anti-(human Protein CS1) (human-mouse HuLuc63 Heavy Chain) consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Anti-(human Protein CS1) (human-mouse HuLuc63 Heavy Chain) is produced in NS0 cells by recombinant DNA technology. Anti-(human Protein CS1) (human-mouse HuLuc63 Heavy Chain) has a theoretical mass of 148.1 kDa for the intact antibody. Anti-(human Protein CS1) (human-mouse HuLuc63 Heavy Chain) was approved on November 30, 2015 by the U.S. Food and Drug Administration. Anti-(human Protein CS1) (human-mouse HuLuc63 Heavy Chain) is marketed under the brand Empliciti™ by Bristol-Myers Squibb.
Table Of contents
| Trade Name | Anti-(human Protein CS1) (human-mouse HuLuc63 Heavy Chain) |
| Availability | Prescription only |
| Generic | Elotuzumab |
| Elotuzumab Other Names | Elotuzumab, HuLuc63, Immunoglobulin G1, anti-(human protein CS1) (human-mouse HuLuc63 heavy chain), disulfide with human-mouse HuLuc63 kappa-chain, dimer |
| Related Drugs | Revlimid, Velcade, Darzalex, Pomalyst, Ninlaro, Kyprolis |
| Type | |
| Formula | C6476H9982N1714O2016S42 |
| Weight | 148100.0 Da |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Anti-(human Protein CS1) (human-mouse HuLuc63 Heavy Chain) is an antineoplastic agent and SLAMF7-directed immunostimulatory antibody used for the treatment of refractory multiple myeloma in combination with other antineoplastic agents.
Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.
Anti-(human Protein CS1) (human-mouse HuLuc63 Heavy Chain) is also used to associated treatment for these conditions: Refractory Multiple Myeloma
How Anti-(human Protein CS1) (human-mouse HuLuc63 Heavy Chain) works
Anti-(human Protein CS1) (human-mouse HuLuc63 Heavy Chain) is a humanized IgG1 monoclonal antibody that specifically targets the SLAMF7 (Signaling Lymphocytic Activation Molecule Family member 7) protein. SLAMF7 is expressed on myeloma cells independent of cytogenetic abnormalities. SLAMF7 is also expressed on Natural Killer cells, plasma cells, and at lower levels on specific immune cell subsets of differentiated cells within the hematopoietic lineage. Anti-(human Protein CS1) (human-mouse HuLuc63 Heavy Chain) directly activates Natural Killer cells through both the SLAMF7 pathway and Fc receptors. Anti-(human Protein CS1) (human-mouse HuLuc63 Heavy Chain) also targets SLAMF7 on myeloma cells and facilitates the interaction with Natural Killer cells to mediate the killing of myeloma cells through antibody-dependent cellular cytotoxicity (ADCC). In preclinical models, the combination of elotuzumab and lenalidomide resulted in enhanced activation of Natural Killer cells that was greater than the effects of either agent alone and increased anti-tumor activity in vitro and in vivo.
Food Interaction
No interactions found.Anti-(human Protein CS1) (human-mouse HuLuc63 Heavy Chain) Hypertension interaction
[Major] The use of monoclonal antibodies administered via IV infusion may cause serious infusion reactions, including bronchospasm, hypoxia, dyspnea, fluctuations in blood pressure, laryngeal edema and pulmonary edema.
Caution should be taken in patients with a history of cardiopulmonary disease as they may require additional post-infusion medications to manage respiratory complications.
It is recommended to administer required intravenous hydration and premedication with antihistamines, analgesics, and antipyretics before administration.
Monitor closely for signs and symptoms of infusion reactions during and for at least 4 hours following completion of each infusion in a setting where cardiopulmonary resuscitation medication and equipment are available.
Immediately interrupt or permanently discontinue treatment and institute supportive management for severe or prolonged infusion reactions as appropriate.
Anti-(human Protein CS1) (human-mouse HuLuc63 Heavy Chain) Drug Interaction
Moderate: lactobacillus acidophilus, pomalidomideUnknown: naproxen, alpha-lipoic acid, aspirin, hydroxyzine, amoxicillin / clavulanate, azithromycin, alpha-d-galactosidase, calcium / vitamin d, calcium / vitamin d, multivitamin with minerals, loratadine, ethanol, loperamide, lenalidomide, tramadol, cyanocobalamin, pyridoxine, zoledronic acid
Anti-(human Protein CS1) (human-mouse HuLuc63 Heavy Chain) Disease Interaction
Major: infections, infusion reactions, tumor lysis syndromeModerate: liver dysfunction
Clearance
The clearance of elotuzumab decreased from a geometric mean (CV%) of 17.5 (21.2%) to 5.8 (31%) mL/day/kg with an increase in dose from 0.5 (i.e., 0.05 times the recommended dosage) to 20 mg/kg (i.e., 2 times the recommended dosage). Based on a population PK model, when elotuzumab is given in combination with lenalidomide and dexamethasone, approximately 97% of the maximum steady-state concentration is predicted to be eliminated with a geometric mean (CV%) of 82.4 (48%) days.
Innovators Monograph
You find simplified version here Anti-(human Protein CS1) (human-mouse HuLuc63 Heavy Chain)
